SPOTLIGHT: Progen axes royalty pact

Progen Industries has killed a pact to share royalties on the experimental tumor drug PI-88, believing it can gain greater value for the therapy as it moves into late-stage trials. Terminating the agreement with Taiwan's Medigen could cost Progen more than $15 million. Medigen will lose its rights to 15 percent of the royalties from PI-88, in exchange for shares, options and some cash. Report

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.